Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 21, Issue 37, 2015, Pages 10621-10635

  Gupta, Vikas ^a   Mah, Xian Jun ^a   Garcia, Maria Carmela ^a   Antonypillai, Christina ^a   Van Der Poorten, David ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Coffee; Diet; Fish; Fish oils; Non alcoholic fatty liver disease; Nonalcoholic steatohepatitis; Nuts; Olive oil; Red wine; Tea; Walnuts

Indexed keywords

FISH OIL; OLIVE OIL; COFFEE; TEA;

AVOCADO; CLINICAL TRIAL (TOPIC); COFFEE; CONTROLLED CLINICAL TRIAL (TOPIC); DIET THERAPY; DIETARY INTAKE; FISH; HUMAN; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; NUT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RED WINE; REVIEW; SYSTEMATIC REVIEW (TOPIC); TEA; WALNUT; ANIMAL; DIET; DISEASE COURSE; END STAGE LIVER DISEASE; LIFESTYLE; METABOLIC SYNDROME X; METABOLISM; PERSEA; RISK; WINE;

ANIMALS; COFFEE; DIET; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FISH OILS; FISHES; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTS; OLIVE OIL; PERSEA; RISK; TEA; WINE;

EID: 84942767679     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i37.10621     Document Type: Review

References (142)

1. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-858 [PMID: 22446927 DOI: 10.1016/j.cgh.2012.03.011]
2. van der Poorten D, George J. Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatol Int 2007;1:343-354 [PMID: 19669329 DOI: 10.1007/s12072-007-9011-8]
3. Barrera F, George J. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis 2014;18:91-112 [PMID: 24274867 DOI: 10.1016/j.cld.2013.09.009]
4. Carvalhana S, Machado MV, Cortez-Pinto H. Improving dietary patterns in patients with nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2012;15:468-473 [PMID: 22878240 DOI: 10.1097/MCO.0b013e3283566614]
5. Bang HO, Dyerberg J, Hjøorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand 1976;200:69-73 [PMID: 961471]
6. Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr 2013;33:231-248 [PMID: 23862644 DOI: 10.1146/annurevnutr-071812-161230]
7. Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010;68:280-289 [PMID: 20500789 DOI: 10.1111/j.1753-4887.2010.00287.x]
8. Bouzianas DG, Bouziana SD, Hatzitolios AI. Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. Nutr Rev 2013;71:753-771 [PMID: 24148001 DOI: 10.1111/nure.12073]
9. Browning LM, Walker CG, Mander AP, West AL, Gambell J, Madden J, Calder PC, Jebb SA. Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans. J Nutr 2014;144:667-672 [PMID: 24647395 DOI: 10.3945/jn. 113.186346]
10. Meyer BJ. Are we consuming enough long chain omega-3 polyunsaturated fatty acids for optimal health? Prostaglandins Leukot Essent Fatty Acids 2011;85:275-280 [PMID: 21571516 DOI: 10.1016/j.plefa.2011.04.010]
11. Papanikolaou Y, Brooks J, Reider C, Fulgoni VL. U. S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational data from NHANES 2003-2008. Nutr J 2014;13:31 [PMID: 24694001 DOI: 10.1186/1475-2891-13-31]
12. Mahaffey KR, Sunderland EM, Chan HM, Choi AL, Grandjean P, Mariën K, Oken E, Sakamoto M, Schoeny R, Weihe P, Yan CH, Yasutake A. Balancing the benefits of n-3 polyunsaturated fatty acids and the risks of methylmercury exposure from fish consumption. Nutr Rev 2011;69:493-508 [PMID: 21884130 DOI: 10.1111/j.1753-4887.2011.00415.x]
13. Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010;31:679-692 [PMID: 20415840 DOI: 10.1111/j.1365-2036.2010.04230.x]
14. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;56:944-951 [PMID: 22023985 DOI: 10.1016/j.jhep. 2011.08.018]
15. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008;42:413-418 [PMID: 18277895 DOI: 10.1097/MCG.0b013e31815591aa]
16. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M; EPE-A Study Group. No significant effects of ethyleicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014;147:377-84.e1 [PMID: 24818764 DOI: 10.1053/j.gastro.2014.04.046]
17. Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R, McCullough AJ. Double-blind randomized placebocontrolled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015;49:137-144 [PMID: 24583757 DOI: 10.1097/MCG.0000000000000099]
18. Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE, Weltman AL, Shah NL, Al-Osaimi AM, Pramoonjago P, Jayakumar S, Binder LP, Simmons-Egolf WD, Burks SG, Bao Y, Taylor AG, Rodriguez J, Caldwell SH. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 2015;62:190-197 [PMID: 25195547 DOI: 10.1016/j.jhep. 2014.08.036]
19. ∗ study. Hepatology 2014;60:1211-1221 [PMID: 25043514 DOI: 10.1002/hep. 27289]
20. Pacifico L, Giansanti S, Gallozzi A, Chiesa C. Long chain omega-3 polyunsaturated fatty acids in pediatric metabolic syndrome. Mini Rev Med Chem 2014;14:791-804 [PMID: 25307311]
21. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Risé P, Galli C, Agostoni C. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011;96:350-353 [PMID: 21233083 DOI: 10.1136/adc.2010.192401]
22. Nobili V, Alisi A, Della Corte C, Risé P, Galli C, Agostoni C, Bedogni G. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis 2013;23:1066-1070 [PMID: 23220074 DOI: 10.1016/j.numecd.2012.10.010]
23. Nobili V, Carpino G, Alisi A, De Vito R, Franchitto A, Alpini G, Onori P, Gaudio E. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One 2014;9:e88005 [PMID: 24505350 DOI: 10.1371/journal.pone.0088005]
24. Harris WS, Pottala JV, Sands SA, Jones PG. Comparison of the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells and plasma phospholipids. Am J Clin Nutr 2007;86:1621-1625 [PMID: 18065578]
25. Lee JH. Polyunsaturated Fatty acids in children. Pediatr Gastroenterol Hepatol Nutr 2013;16:153-161 [PMID: 24224148 DOI: 10.5223/pghn. 2013.16.3.153]
26. Weinberg BA, Bealer BK. The world of caffeine: the science and culture of the world's most popular drug. New York: Routledge, 2001
27. Yesil A, Yilmaz Y. Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;38:1038-1044 [PMID: 24024834 DOI: 10.1111/apt.12489]
28. Torres DM, Harrison SA. Is it time to write a prescription for coffee? Coffee and liver disease. Gastroenterology 2013;144:670-672 [PMID: 23453671 DOI: 10.1053/j.gastro.2013.02.015]
29. Chen S, Teoh NC, Chitturi S, Farrell GC. Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? J Gastroenterol Hepatol 2014;29:435-441 [PMID: 24199670 DOI: 10.1111/jgh.12422]
30. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992;136:1248-1257 [PMID: 1476147]
31. Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. Association of coffee drinking with total and cause-specific mortality. N Engl J Med 2012;366:1891-1904 [PMID: 22591295 DOI: 10.1056/NEJMoa1112010]
32. Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006;166:1190-1195 [PMID: 16772246 DOI: 10.1001/archinte.166.11.1190]
33. Corrao G, Zambon A, Bagnardi V, D'Amicis A, Klatsky A; Collaborative SIDECIR Group. Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol 2001;11:458-465 [PMID: 11557177]
34. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005;129:1928-1936 [PMID: 16344061 DOI: 10.1053/j.gastro.2005.08.056]
35. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009;50:1360-1369 [PMID: 19676128 DOI: 10.1002/hep. 23162]
36. Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C TRIAL GROUP. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011;140:1961-1969 [PMID: 21376050 DOI: 10.1053/j.gastro.2011.02.061]
37. Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML, Trevisi P, Martelli C, Nardi G, Donato F; Brescia HCC Study Group. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 2005;42:528-534 [PMID: 15868652]
38. Hu G, Tuomilehto J, Pukkala E, Hakulinen T, Antikainen R, Vartiainen E, Jousilahti P. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 2008;48:129-136 [PMID: 18537182 DOI: 10.1002/hep. 22320]
39. Sang LX, Chang B, Li XH, Jiang M. Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterol 2013;13:34 [PMID: 23433483 DOI: 10.1186/1471-230X-13-34]
40. Klatsky AL, Armstrong MA, Friedman GD. Coffee, tea, and mortality. Ann Epidemiol 1993;3:375-381 [PMID: 8275213]
41. La Vecchia C, Negri E, Cavalieri d'Oro L, Franceschi S. Liver cirrhosis and the risk of primary liver cancer. Eur J Cancer Prev 1998;7:315-320 [PMID: 9806120]
42. Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La Vecchia C, Lagiou P, Trichopoulos D. Does coffee protect against hepatocellular carcinoma? Br J Cancer 2002;87:956-959 [PMID: 12434283 DOI: 10.1038/sj.bjc.6600582]
43. Ding M, Bhupathiraju SN, Chen M, van Dam RM, Hu FB. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes Care 2014;37:569-586 [PMID: 24459154 DOI: 10.2337/dc13-1203]
44. Ding M, Bhupathiraju SN, Satija A, van Dam RM, Hu FB. Longterm coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 2014;129:643-659 [PMID: 24201300 DOI: 10.1161/CIRCULATIONAHA.113.005925]
45. Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol 2014;20:12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956]
46. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357-1365 [PMID: 23175136 DOI: 10.1002/hep. 26156]
47. Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;35:76-82 [PMID: 22059453 DOI: 10.1111/j.1365-2036.2011.04916.x]
48. Anty R, Marjoux S, Iannelli A, Patouraux S, Schneck AS, Bonnafous S, Gire C, Amzolini A, Ben-Amor I, Saint-Paul MC, Mariné-Barjoan E, Pariente A, Gugenheim J, Gual P, Tran A. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012;57:1090-1096 [PMID: 22820478 DOI: 10.1016/j.jhep. 2012.07.014]
49. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005;128:24-32 [PMID: 15633120]
50. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012;55:429-436 [PMID: 21987293 DOI: 10.1002/hep. 24731]
51. Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int 2014;34:1250-1258 [PMID: 24267865 DOI: 10.1111/liv. 12379]
52. Casas-Agustench P, Salas-Huetos A, Salas-Salvadó J. Mediterranean nuts: origins, ancient medicinal benefits and symbolism. Public Health Nutr 2011;14:2296-2301 [PMID: 22166187 DOI: 10.1017/S1368980011002540]
53. Ros E. Health benefits of nut consumption. Nutrients 2010;2:652-682 [PMID: 22254047 DOI: 10.3390/nu2070683]
54. Maguire LS, O'Sullivan SM, Galvin K, O'Connor TP, O'Brien NM. Fatty acid profile, tocopherol, squalene and phytosterol content of walnuts, almonds, peanuts, hazelnuts and the macadamia nut. Int J Food Sci Nutr 2004;55:171-178 [PMID: 15223592 DOI: 10.1080/09637480410001725175]
55. Kornsteiner M, Wagner KH, Elmadfa I. Tocopherols and total phenolics in 10 different nut types. Food Chemistry 2006;98:381-387 [DOI: 10.1016/j.foodchem.2005.07.033]
56. Rainey C, Nyquist L. Nuts-Nutrition and Health Benefits of Daily Use. Nutrition Today 1997;32:157-163 [DOI: 10.1097/00017285-199707000-00006]
57. Chen CY, Blumberg JB. Phytochemical composition of nuts. Asia Pac J Clin Nutr 2008;17 Suppl 1:329-332 [PMID: 18296370]
58. King JC, Blumberg J, Ingwersen L, Jenab M, Tucker KL. Tree nuts and peanuts as components of a healthy diet. J Nutr 2008;138:1736S-1740S [PMID: 18716178]
59. Blomhoff R, Carlsen MH, Andersen LF, Jacobs DR. Health benefits of nuts: potential role of antioxidants. Br J Nutr 2006;96 Suppl 2:S52-S60 [PMID: 17125534]
60. Fraser GE, Sabaté J, Beeson WL, Strahan TM. A possible protective effect of nut consumption on risk of coronary heart disease. The Adventist Health Study. Arch Intern Med 1992;152:1416-1424 [PMID: 1627021 DOI: 10.1001/archinte.152.7.1416]
61. Albert CM, Gaziano JM, Willett WC, Manson JE. Nut consumption and decreased risk of sudden cardiac death in the Physicians' Health Study. Arch Intern Med 2002;162:1382-1387 [PMID: 12076237 DOI: 10.1001/archinte.162.12.1382]
62. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279-1290 [PMID: 23432189 DOI: 10.1056/NEJMoa1200303]
63. Hu FB, Stampfer MJ, Manson JE, Rimm EB, Colditz GA, Rosner BA, Speizer FE, Hennekens CH, Willett WC. Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study. BMJ 1998;317:1341-1345 [PMID: 9812929 DOI: 10.1136/bmj.317.7169.1341]
64. Li TY, Brennan AM, Wedick NM, Mantzoros C, Rifai N, Hu FB. Regular consumption of nuts is associated with a lower risk of cardiovascular disease in women with type 2 diabetes. J Nutr 2009;139:1333-1338 [PMID: 19420347 DOI: 10.3945/jn. 108.103622]
65. Lovejoy JC, Most MM, Lefevre M, Greenway FL, Rood JC. Effect of diets enriched in almonds on insulin action and serum lipids in adults with normal glucose tolerance or type 2 diabetes. Am J Clin Nutr 2002;76:1000-1006 [PMID: 12399271]
66. Sabaté J, Haddad E, Tanzman JS, Jambazian P, Rajaram S. Serum lipid response to the graduated enrichment of a Step I diet with almonds: a randomized feeding trial. Am J Clin Nutr 2003;77:1379-1384 [PMID: 12791613]
67. Ros E, Núñez I, Pérez-Heras A, Serra M, Gilabert R, Casals E, Deulofeu R. A walnut diet improves endothelial function in hypercholesterolemic subjects: a randomized crossover trial. Circulation 2004;109:1609-1614 [PMID: 15037535 DOI: 10.1161/01. CIR.0000124477.91474. FF]
68. Gebauer SK, West SG, Kay CD, Alaupovic P, Bagshaw D, Kris-Etherton PM. Effects of pistachios on cardiovascular disease risk factors and potential mechanisms of action: a dose-response study. Am J Clin Nutr 2008;88:651-659 [PMID: 18779280]
69. Bes-Rastrollo M, Sabaté J, Gómez-Gracia E, Alonso A, Martínez JA, Martínez-González MA. Nut consumption and weight gain in a Mediterranean cohort: The SUN study. Obesity (Silver Spring) 2007;15:107-116 [PMID: 17228038 DOI: 10.1038/oby.2007.507]
70. Ibarrola-Jurado N, Bulló M, Guasch-Ferré M, Ros E, Martínez-González MA, Corella D, Fiol M, Wärnberg J, Estruch R, Román P, Arós F, Vinyoles E, Serra-Majem L, Pintó X, Covas MI, Basora J, Salas-Salvadó J. Cross-sectional assessment of nut consumption and obesity, metabolic syndrome and other cardiometabolic risk factors: the PREDIMED study. PLoS One 2013;8:e57367 [PMID: 23460844 DOI: 10.1371/journal.pone.0057367]
71. Jiang R, Manson JE, Stampfer MJ, Liu S, Willett WC, Hu FB. Nut and peanut butter consumption and risk of type 2 diabetes in women. JAMA 2002;288:2554-2560 [PMID: 12444862 DOI: 10.1001/jama.288.20.2554]
72. Pan A, Sun Q, Manson JE, Willett WC, Hu FB. Walnut consumption is associated with lower risk of type 2 diabetes in women. J Nutr 2013;143:512-518 [PMID: 23427333 DOI: 10.3945/jn. 112.172171]
73. Djoussé L, Rudich T, Gaziano JM. Nut consumption and risk of hypertension in US male physicians. Clin Nutr 2009;28:10-14 [PMID: 18834651 DOI: 10.1016/j.clnu.2008.08.005]
74. O'Neil CE, Keast DR, Nicklas TA, Fulgoni VL. Nut consumption is associated with decreased health risk factors for cardiovascular disease and metabolic syndrome in U. S. adults: NHANES 1999-2004. J Am Coll Nutr 2011;30:502-510 [PMID: 22331685 DOI: 10.1080/07315724.2011.10719996]
75. Bao Y, Han J, Hu FB, Giovannucci EL, Stampfer MJ, Willett WC, Fuchs CS. Association of nut consumption with total and causespecific mortality. N Engl J Med 2013;369:2001-2011 [PMID: 24256379 DOI: 10.1056/NEJMoa1307352]
76. Barrera F, George J, van der Poorten D, St George A. Dietary changes in patients with non-alcoholic fatty liver disease are independently associated with improvement in liver function tests. Hepatology 2012;56:889A-889A [DOI: 10.1002/hep. 26040]
77. Han JM, Jo AN, Lee SM, Bae HS, Jun. DW, Cho YK, Suk KT, Yoon JH, Ahn SB, Cho YJ, Kim SW, Jang EC. Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2014;29:1265-1272 [PMID: 24955455 DOI: 10.1111/jgh.12520]
78. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]
79. Calpe-Berdiel L, Escolà-Gil JC, Blanco-Vaca F. New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism. Atherosclerosis 2009;203:18-31 [PMID: 18692849 DOI: 10.1016/j.atherosclerosis.2008.06.026]
80. Casas-Agustench P, López-Uriarte P, Bulló M, Ros E, Cabré-Vila JJ, Salas-Salvadó J. Effects of one serving of mixed nuts on serum lipids, insulin resistance and inflammatory markers in patients with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2011;21:126-135 [PMID: 20031380 DOI: 10.1016/j.numecd.2009.08.005]
81. Wien MA, Sabaté JM, Iklé DN, Cole SE, Kandeel FR. Almonds vs complex carbohydrates in a weight reduction program. Int J Obes Relat Metab Disord 2003;27:1365-1372 [PMID: 14574348 DOI: 10.1038/sj.ijo.0802411]
82. Masterjohn C, Bruno RS. Therapeutic potential of green tea in nonalcoholic fatty liver disease. Nutr Rev 2012;70:41-56 [PMID: 22221215 DOI: 10.1111/j.1753-4887.2011.00440.x]
83. Imai K, Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. BMJ 1995;310:693-696 [PMID: 7711535]
84. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, Tsubono Y, Tsuji I. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006;296:1255-1265 [PMID: 16968850 DOI: 10.1001/jama.296.10.1255]
85. Sakata R, Nakamura T, Torimura T, Ueno T, Sata M. Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: a double-blind placebo-controlled study. Int J Mol Med 2013;32:989-994 [PMID: 24065295 DOI: 10.3892/ijmm.2013.1503]
86. Park HJ, Lee JY, Chung MY, Park YK, Bower AM, Koo SI, Giardina C, Bruno RS. Green tea extract suppresses NFκB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis. J Nutr 2012;142:57-63 [PMID: 22157544 DOI: 10.3945/jn. 111.148544]
87. Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, Fung ML, Tipoe GL. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr 2014;53:187-199 [PMID: 23515587 DOI: 10.1007/s00394-013-0516-8]
88. Karmakar S, Das D, Maiti A, Majumdar S, Mukherjee P, Das AS, Mitra C. Black tea prevents high fat diet-induced non-alcoholic steatohepatitis. Phytother Res 2011;25:1073-1081 [PMID: 21452373 DOI: 10.1002/ptr.3466]
89. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, Mastrangelo S. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009;65:331-341 [PMID: 19198822 DOI: 10.1007/s00228-008-0610-7]
90. Cooper R, Morre DJ, Morre DM. Medicinal benefits of green tea: Part I. Review of noncancer health benefits. J Altern Complement Med 2005;11:521-528 [PMID: 15992239 DOI: 10.1089/acm.2005.11.521]
91. Robinson J. The Oxford companion to wine. 3rd ed. Oxford: Oxford University Press, 2006
92. Hoffman R, Gerber M. The Mediterranean diet. Chichester, West Sussex, UK: Wiley-Blackwell, 2012
93. Borriello A, Bencivenga D, Caldarelli I, Tramontano A, Borgia A, Zappia V, Della Ragione F. Resveratrol: from basic studies to bedside. Cancer Treat Res 2014;159:167-184 [PMID: 24114480 DOI: 10.1007/978-3-642-38007-5-10]
94. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des 2013;19:6064-6093 [PMID: 23448440]
95. Theobald H, Bygren LO, Carstensen J, Engfeldt P. A moderate intake of wine is associated with reduced total mortality and reduced mortality from cardiovascular disease. J Stud Alcohol 2000;61:652-656 [PMID: 11022802]
96. Ruf JC. Overview of epidemiological studies on wine, health and mortality. Drugs Exp Clin Res 2003;29:173-179 [PMID: 15134372]
97. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009;13:9-19 [PMID: 19240815]
98. Auger C, Caporiccio B, Landrault N, Teissedre PL, Laurent C, Cros G, Besancon P, Rouanet JM. Red wine phenolic compounds reduce plasma lipids and apolipoprotein B and prevent early aortic atherosclerosis in hypercholesterolemic golden Syrian hamsters (Mesocricetus auratus). J Nutr 2002;132:1207-1213 [PMID: 12042435]
99. Agouni A, Lagrue-Lak-Hal AH, Mostefai HA, Tesse A, Mulder P, Rouet P, Desmoulin F, Heymes C, Martinez MC, Andriantsitohaina R. Red wine polyphenols prevent metabolic and cardiovascular alterations associated with obesity in Zucker fatty rats (Fa/Fa). PLoS One 2009;4:e5557 [PMID: 19440378 DOI: 10.1371/journal.pone.0005557]
100. Senault C, Betoulle D, Luc G, Hauw P, Rigaud D, Fumeron F. Beneficial effects of a moderate consumption of red wine on cellular cholesterol efflux in young men. Nutr Metab Cardiovasc Dis 2000;10:63-69 [PMID: 10919170]
101. Hansen AS, Marckmann P, Dragsted LO, Finne Nielsen IL, Nielsen SE, Gronbaek M. Effect of red wine and red grape extract on blood lipids, haemostatic factors, and other risk factors for cardiovascular disease. Eur J Clin Nutr 2005;59:449-455 [PMID: 15674304 DOI: 10.1038/sj.ejcn. 1602107]
102. Kechagias S, Zanjani S, Gjellan S, Leinhard OD, Kihlberg J, Smedby O, Johansson L, Kullberg J, Ahlstrom H, Lindstrom T, Nystrom FH. Effects of moderate red wine consumption on liver fat and blood lipids: a prospective randomized study. Ann Med 2011;43:545-554 [PMID: 21599573 DOI: 10.3109/07853890.201 1.588246]
103. Pal S, Ho N, Santos C, Dubois P, Mamo J, Croft K, Allister E. Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. J Nutr 2003;133:700-706 [PMID: 12612140]
104. Napoli R, Cozzolino D, Guardasole V, Angelini V, Zarra E, Matarazzo M, Cittadini A, Sacca L, Torella R. Red wine consumption improves insulin resistance but not endothelial function in type 2 diabetic patients. Metabolism 2005;54:306-313 [PMID: 15736107 DOI: 10.1016/j.metabol.2004.09.010]
105. Chiva-Blanch G, Urpi-Sarda M, Ros E, Valderas-Martinez P, Casas R, Arranz S, Guillen M, Lamuela-Raventos RM, Llorach R, Andres-Lacueva C, Estruch R. Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial. Clin Nutr 2013;32:200-206 [PMID: 22999066 DOI: 10.1016/j.clnu.2012.08.022]
106. Al-Awwadi NA, Bornet A, Azay J, Araiz C, Delbosc S, Cristol JP, Linck N, Cros G, Teissedre PL. Red wine polyphenols alone or in association with ethanol prevent hypertension, cardiac hypertrophy, and production of reactive oxygen species in the insulin-resistant fructose-fed rat. J Agric Food Chem 2004;52:5593-5597 [PMID: 15373398 DOI: 10.1021/jf049295g]
107. Su HC, Hung LM, Chen JK. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2006;290:E1339-E1346 [PMID: 16434553 DOI: 10.1152/ajpendo.00487.2005]
108. Vazquez-Prieto MA, Renna NF, Diez ER, Cacciamani V, Lembo C, Miatello RM. Effect of red wine on adipocytokine expression and vascular alterations in fructose-fed rats. Am J Hypertens 2011;24:234-240 [PMID: 20885371 DOI: 10.1038/ajh.2010.214]
109. Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, El May M, Gharbi N, Kamoun A, El-Fazaa S. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci 2007;80:1033-1039 [PMID: 17258234 DOI: 10.1016/j.lfs.2006.11.044]
110. Morton JF, Dowling C. Fruits of warm climates. Miami, FL: Florida Flair Books, 1987
111. Yasir M, Das S, Kharya MD. The phytochemical and pharmacological profile of Persea americana Mill. Pharmacogn Rev 2010;4:77-84 [PMID: 22228945 DOI: 10.4103/0973-7847.65332]
112. Al-Dosari MS. Hypolipidemic and antioxidant activities of avocado fruit pulp on high cholesterol fed diet in rats. J Pharm Pharmacol 2011;5:1475-1483 [DOI: 10.5897/AJPP11.239]
113. Guzman-Rodriguez JJ, Lopez-Gomez R, Suarez-Rodriguez LM, Salgado-Garciglia R, Rodriguez-Zapata LC, Ochoa-Zarzosa A, Lopez-Meza JE. Antibacterial activity of defensin PaDef from avocado fruit (Persea americana var. drymifolia) expressed in endothelial cells against Escherichia coli and Staphylococcus aureus. Biomed Res Int 2013;2013:986273 [PMID: 24319695 DOI: 10.1155/2013/986273]
114. Dreher ML, Davenport AJ. Hass avocado composition and potential health effects. Crit Rev Food Sci Nutr 2013;53:738-750 [PMID: 23638933 DOI: 10.1080/10408398.2011.556759]
115. Roberts RL, Green J, Lewis B. Lutein and zeaxanthin in eye and skin health. Clin Dermatol 2009;27:195-201 [PMID: 19168000 DOI: 10.1016/j.clindermatol.2008.01.011]
116. Rosenblat G, Meretski S, Segal J, Tarshis M, Schroeder A, Zanin-Zhorov A, Lion G, Ingber A, Hochberg M. Polyhydroxylated fatty alcohols derived from avocado suppress inflammatory response and provide non-sunscreen protection against UV-induced damage in skin cells. Arch Dermatol Res 2011;303:239-246 [PMID: 20978772 DOI: 10.1007/s00403-010-1088-6]
117. Carvajal-Zarrabal O, Nolasco-Hipolito C, Aguilar-Uscanga MG, Melo-Santiesteban G, Hayward-Jones PM, Barradas-Dermitz DM. Avocado oil supplementation modifies cardiovascular risk profile markers in a rat model of sucrose-induced metabolic changes. Dis Markers 2014;2014:386425 [PMID: 24719499 DOI: 10.1155/2014/386425]
118. Fulgoni VL, Dreher M, Davenport AJ. Avocado consumption is associated with better diet quality and nutrient intake, and lower metabolic syndrome risk in US adults: results from the National Health and Nutrition Examination Survey (NHANES) 2001-2008. Nutr J 2013;12:1 [PMID: 23282226 DOI: 10.1186/1475-2891-12-1]
119. Unlu NZ, Bohn T, Clinton SK, Schwartz SJ. Carotenoid absorption from salad and salsa by humans is enhanced by the addition of avocado or avocado oil. J Nutr 2005;135:431-436 [PMID: 15735074]
120. Pahua-Ramos ME, Garduno-Siciliano L, Dorantes-Alvarez L, Chamorro-Cevallos G, Herrera-Martinez J, Osorio-Esquivel O, Ortiz-Moreno A. Reduced-calorie avocado paste attenuates metabolic factors associated with a hypercholesterolemic-high fructose diet in rats. Plant Foods Hum Nutr 2014;69:18-24 [PMID: 24249159 DOI: 10.1007/s11130-013-0395-4]
121. Naveh E, Werman MJ, Sabo E, Neeman I. Defatted avocado pulp reduces body weight and total hepatic fat but increases plasma cholesterol in male rats fed diets with cholesterol. J Nutr 2002;132:2015-2018 [PMID: 12097685]
122. Kawagishi H, Fukumoto Y, Hatakeyama M, He P, Arimoto H, Matsuzawa T, Arimoto Y, Suganuma H, Inakuma T, Sugiyama K. Liver injury suppressing compounds from avocado (Persea americana). J Agric Food Chem 2001;49:2215-2221 [PMID: 11368579]
123. Gatselis NK, Ntaios G, Makaritsis K, Dalekos GN. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med 2014;14:121-131 [PMID: 23292294 DOI: 10.1007/s10238-012-0227-0]
124. Padmanabhan M, Arumugam G. Effect of Persea americana (avocado) fruit extract on the level of expression of adiponectin and PPAR-γ in rats subjected to experimental hyperlipidemia and obesity. J Complement Integr Med 2014;11:107-119 [PMID: 24770838 DOI: 10.1515/jcim-2013-0053]
125. Ding H, Han C, Guo D, Chin YW, Ding Y, Kinghorn AD, D'Ambrosio SM. Selective induction of apoptosis of human oral cancer cell lines by avocado extracts via a ROS-mediated mechanism. Nutr Cancer 2009;61:348-356 [PMID: 19373608 DOI: 10.1080/01635580802567158]
126. Tapiero H, Townsend DM, Tew KD. The role of carotenoids in the prevention of human pathologies. Biomed Pharmacother 2004;58:100-110 [PMID: 14992791 DOI: 10.1016/j.biopha.2003.12.006]
127. Vega D. The History Of Olive Oil - Kaufmann Mercantile [Internet]. Kaufmann Mercantile 2010 [cited 2015 Jan 16]. Available from: URL: http://kaufmann-mercantile.com/the-history-of-olive-oil/Vega D
128. Covas MI. Olive oil and the cardiovascular system. Pharmacol Res 2007;55:175-186 [PMID: 17321749 DOI: 10.1016/j.phrs.2007.01.010]
129. Buckland G, Mayen AL, Agudo A, Travier N, Navarro C, Huerta JM, Chirlaque MD, Barricarte A, Ardanaz E, Moreno-Iribas C, Marin P, Quiros JR, Redondo ML, Amiano P, Dorronsoro M, Arriola L, Molina E, Sanchez MJ, Gonzalez CA. Olive oil intake and mortality within the Spanish population (EPIC-Spain). Am J Clin Nutr 2012;96:142-149 [PMID: 22648725 DOI: 10.3945/ajcn. 111.024216]
130. Pelucchi C, Bosetti C, Negri E, Lipworth L, La Vecchia C. Olive oil and cancer risk: an update of epidemiological findings through 2010. Curr Pharm Des 2011;17:805-812 [PMID: 21443483]
131. Nordmann AJ, Suter-Zimmermann K, Bucher HC, Shai I, Tuttle KR, Estruch R, Briel M. Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med 2011;124:841-51.e2 [PMID: 21854893 DOI: 10.1016/j.amjmed.2011.04.024]
132. Sofi F, Giangrandi I, Cesari F, Corsani I, Abbate R, Gensini GF, Casini A. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr 2010;61:792-802 [PMID: 20465434 DOI: 10.3109/09637486.201 0.487480]
133. Nigam P, Bhatt S, Misra A, Chadha DS, Vaidya M, Dasgupta J, Pasha QM. Effect of a 6-month intervention with cooking oils containing a high concentration of monounsaturated fatty acids (olive and canola oils) compared with control oil in male Asian Indians with nonalcoholic fatty liver disease. Diabetes Technol Ther 2014;16:255-261 [PMID: 24625239 DOI: 10.1089/dia.2013.0178]
134. Bozzetto L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A, Mazzarella R, Longobardo M, Mancini M, Vigorito C, Riccardi G, Rivellese AA. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 2012;35:1429-1435 [PMID: 22723581 DOI: 10.2337/dc12-0033]
135. Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol 2014;20:16831-16840 [PMID: 25492997 DOI: 10.3748/wjg.v20.i45.16831]
136. Mohamed AI, Hussein AS, Bhathena SJ, Hafez YS. The effect of dietary menhaden, olive, and coconut oil fed with three levels of vitamin E on plasma and liver lipids and plasma fatty acid composition in rats. J Nutr Biochem 2002;13:435-441 [PMID: 12121831 DOI: 10.1016/S0955-2863 (02) 00196-1]
137. Park S, Choi Y, Um SJ, Yoon SK, Park T. Oleuropein attenuates hepatic steatosis induced by high-fat diet in mice. J Hepatol 2011;54:984-993 [PMID: 21145829 DOI: 10.1016/j.jhep. 2010.08.019]
138. Ronis MJ, Baumgardner JN, Marecki JC, Hennings L, Wu X, Shankar K, Cleves MA, Gomez-Acevedo H, Badger TM. Dietary fat source alters hepatic gene expression profile and determines the type of liver pathology in rats overfed via total enteral nutrition. Physiol Genomics 2012;44:1073-1089 [PMID: 22991207 DOI: 10.1152/physiolgenomics.00069.2012]
139. De La Cruz JP, Quintero L, Villalobos MA, Sanchez de la Cuesta F. Lipid peroxidation and glutathione system in hyperlipemic rabbits: influence of olive oil administration. Biochim Biophys Acta 2000;1485:36-44 [PMID: 10802247]
140. Kasdallah-Grissa A, Nakbi A, Koubaa N, El-Fazaa S, Gharbi N, Kamoun A, Hammami M. Dietary virgin olive oil protects against lipid peroxidation and improves antioxidant status in the liver of rats chronically exposed to ethanol. Nutr Res 2008;28:472-479 [PMID: 19083448 DOI: 10.1016/j.nutres.2008.03.014]
141. Ferramosca A, Savy V, Zara V. Olive oil increases the hepatic triacylglycerol content in mice by a distinct influence on the synthesis and oxidation of fatty acids. Biosci Biotechnol Biochem 2008;72:62-69 [PMID: 18175925 DOI: 10.1271/bbb.70369]
142. Nakbi A, Tayeb W, Grissa A, Issaoui M, Dabbou S, Chargui I, Ellouz M, Miled A, Hammami M. Effects of olive oil and its fractions on oxidative stress and the liver's fatty acid composition in 2, 4-Dichlorophenoxyacetic acid-treated rats. Nutr Metab (Lond) 2010;7:80 [PMID: 21034436 DOI: 10.1186/1743-7075-7-80]